ALL relapse after anti-CD19 CAR-T cells therapy in a young adult: which therapeutic options? - Archive ouverte HAL Access content directly
Conference Poster Year :

ALL relapse after anti-CD19 CAR-T cells therapy in a young adult: which therapeutic options?

(1, 2) , (1) , (3) , (3) , (3) , (4) , (1)
1
2
3
4

Abstract

T-cells expressing a Chimeric Antigen Receptor (CAR) recognizing the CD19 antigen allowed high early response rates in high-risk B acute lymphoblastic leukemias (B-ALL). Nevertheless, 35% to 44% of patients relapse. Among the mechanisms of immune evasion in CD19+ relapses of ALL, expression and secretion of molecules inhibiting cytotoxic T-lymphocytes, or lack of expression of co-stimulatory molecules, have been described. Expansion, persistence and cytotoxic activity of CAR-T cells could also be deficient. Here, we present the case of a young adult who presented successive relapses of ALL after chemotherapy, hematopoietic stem cell transplant (HSCT) and anti-CD19 CAR-T cells. An extended immunophenotype of leukemic cells and sensitivity to anti-CD19 CAR-T cells mediated lysis are analysed.
Fichier principal
Vignette du fichier
Poster GRAIN.pdf (730.34 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03877258 , version 1 (29-11-2022)

Identifiers

  • HAL Id : inserm-03877258 , version 1

Cite

Audrey Grain, Jocelyn Ollier, Thierry Guillaume, Patrice Chevallier, Baptiste Le Calvez, et al.. ALL relapse after anti-CD19 CAR-T cells therapy in a young adult: which therapeutic options?. Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Nov 2022, Bordeaux, France. ⟨inserm-03877258⟩
0 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More